Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study
Identifieur interne : 003365 ( PascalFrancis/Corpus ); précédent : 003364; suivant : 003366Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study
Auteurs : Nicolas Andre ; Angelique Rome ; Carole Coze ; Laetitia Padovani ; Eddy Pasquier ; Laurence Camoin ; Jean Claude GentetSource :
- Clinical therapeutics [ 0149-2918 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: Metronomic chemotherapy (MC) is the administration of chemotherapy at doses below the maximal tolerated dose on a frequent schedule of administration, with no prolonged drug-free breaks. Objective: The aim of this research was to assess the effectiveness and tolerance of a metronomic etoposide/ cyclophosphamide/celecoxib regimen in children and adolescents with refractory cancer. Methods: This retrospective, single-center study evaluated the use of MC with etoposide 25 mg/m2. d-1 (days 1-14), cyclophosphamide 25 mg/m2. d-1 (days 15-28), and celecoxib 100 to 400 mg/d (days 1-28), in children with refractory, or high-risk relapsing, cancer. Adverse events were determined through laboratory analyses and investigator observations. Results: From January 2005 to December 2007, 17 children and adolescents were treated. The best responses observed were stabilizations of the disease that lasted over 20 weeks in 7 patients (41%). Most importantly, in 4 patients (24%) antalgic treatment could be transiently diminished or stopped, and in 1 patient (6%) oxygen support could be stopped for several weeks. Four grade IV platelet toxicities were noted in 3 patients; 2 grade IV anemia occurred in 2 patients (who had platelet and red blood cell transfusions before initiation of treatment); and 1 patient had grade III neutropenia. No other grade III or IV toxicities were noted. Grade II alopecia and stomatitis were observed in 1 patient and grade II vomiting was observed in 2 patients. One patient with meningeal carcinomatosis developed bilateral subdural hematoma for which the role of MC could not be ruled out. Circulating endothelial cells were elevated in 3 out of 3 patients in whom they were quantified and who were progressing while under MC. Conclusion: The MC regimen we report here was associated with disease stabilization without major toxicities. This assessment of MC in children and adolescents warrants further studies.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 08-0399816 INIST |
|---|---|
| ET : | Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study |
| AU : | ANDRE (Nicolas); ROME (Angelique); COZE (Carole); PADOVANI (Laetitia); PASQUIER (Eddy); CAMOIN (Laurence); GENTET (Jean Claude) |
| AF : | Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone/Marseille/France (1 aut., 2 aut., 3 aut., 7 aut.); INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille/Marseille/France (1 aut., 5 aut.); Service de Radiothérapie, Hôpital de La Timone/Marseille/France (4 aut.); Children's Cancer Institute Australia, Pharmacoproteomics Croup, Children's Hospital/Randwick/Australie (5 aut.); Laboratoire d'hématologie, Hôpital de la Conception/Marseille/France (6 aut.) |
| DT : | Publication en série; Correspondance, lettre; Niveau analytique |
| SO : | Clinical therapeutics; ISSN 0149-2918; Etats-Unis; Da. 2008; Vol. 30; No. 7; Pp. 1336-1340; Bibl. 12 ref. |
| LA : | Anglais |
| EA : | Background: Metronomic chemotherapy (MC) is the administration of chemotherapy at doses below the maximal tolerated dose on a frequent schedule of administration, with no prolonged drug-free breaks. Objective: The aim of this research was to assess the effectiveness and tolerance of a metronomic etoposide/ cyclophosphamide/celecoxib regimen in children and adolescents with refractory cancer. Methods: This retrospective, single-center study evaluated the use of MC with etoposide 25 mg/m2. d-1 (days 1-14), cyclophosphamide 25 mg/m2. d-1 (days 15-28), and celecoxib 100 to 400 mg/d (days 1-28), in children with refractory, or high-risk relapsing, cancer. Adverse events were determined through laboratory analyses and investigator observations. Results: From January 2005 to December 2007, 17 children and adolescents were treated. The best responses observed were stabilizations of the disease that lasted over 20 weeks in 7 patients (41%). Most importantly, in 4 patients (24%) antalgic treatment could be transiently diminished or stopped, and in 1 patient (6%) oxygen support could be stopped for several weeks. Four grade IV platelet toxicities were noted in 3 patients; 2 grade IV anemia occurred in 2 patients (who had platelet and red blood cell transfusions before initiation of treatment); and 1 patient had grade III neutropenia. No other grade III or IV toxicities were noted. Grade II alopecia and stomatitis were observed in 1 patient and grade II vomiting was observed in 2 patients. One patient with meningeal carcinomatosis developed bilateral subdural hematoma for which the role of MC could not be ruled out. Circulating endothelial cells were elevated in 3 out of 3 patients in whom they were quantified and who were progressing while under MC. Conclusion: The MC regimen we report here was associated with disease stabilization without major toxicities. This assessment of MC in children and adolescents warrants further studies. |
| CC : | 002B02 |
| FD : | Etoposide; Cyclophosphamide; Anticancéreux; Célécoxib; Protocole thérapeutique; Enfant; Adolescent; Résistance traitement; Tumeur maligne; Cancérologie; Cellule endothéliale; Antiinflammatoire non stéroïde; Gène sis; Chimiothérapie métronomique |
| FG : | Homme; Cancer; Antimitotique; DNA topoisomerase (ATP-hydrolysing); Isomerases; Enzyme; Inhibiteur enzyme; Dérivé de la podophyllotoxine; Inhibiteur de la topoisomérase II; Agent alkylant; Moutarde à l'azote; Dérivé de l'oxazaphosphinane; Inhibiteur cyclooxygenase 2; Prostaglandin-endoperoxide synthase; Oxidoreductases |
| ED : | Etoposide; Cyclophosphamide; Antineoplastic agent; Celecoxib; Therapeutic protocol; Child; Adolescent; Treatment resistance; Malignant tumor; Cancerology; Endothelial cell; Non steroidal antiinflammatory agent; Metronomic chemotherapy |
| EG : | Human; Cancer; Antimitotic; DNA topoisomerase (ATP-hydrolysing); Isomerases; Enzyme; Enzyme inhibitor; Podophyllotoxin derivatives; Topoisomerase II inhibitor; Alkylating agent; Nitrogen mustard; Oxazaphosphinane derivatives; Cyclooxygenase 2 inhibitor; Prostaglandin-endoperoxide synthase; Oxidoreductases |
| SD : | Etopósido; Ciclofosfamida; Anticanceroso; Celecoxib; Protocolo terapéutico; Niño; Adolescente; Resistencia tratamiento; Tumor maligno; Cancerología; Célula endotelial; Antiinflamatorio no esteroide |
| LO : | INIST-18353.354000196281980150 |
| ID : | 08-0399816 |
Links to Exploration step
Pascal:08-0399816Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study</title><author><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="Andre">Nicolas Andre</name><affiliation><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rome, Angelique" sort="Rome, Angelique" uniqKey="Rome A" first="Angelique" last="Rome">Angelique Rome</name><affiliation><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Coze, Carole" sort="Coze, Carole" uniqKey="Coze C" first="Carole" last="Coze">Carole Coze</name><affiliation><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Padovani, Laetitia" sort="Padovani, Laetitia" uniqKey="Padovani L" first="Laetitia" last="Padovani">Laetitia Padovani</name><affiliation><inist:fA14 i1="03"><s1>Service de Radiothérapie, Hôpital de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pasquier, Eddy" sort="Pasquier, Eddy" uniqKey="Pasquier E" first="Eddy" last="Pasquier">Eddy Pasquier</name><affiliation><inist:fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Children's Cancer Institute Australia, Pharmacoproteomics Croup, Children's Hospital</s1><s2>Randwick</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Camoin, Laurence" sort="Camoin, Laurence" uniqKey="Camoin L" first="Laurence" last="Camoin">Laurence Camoin</name><affiliation><inist:fA14 i1="05"><s1>Laboratoire d'hématologie, Hôpital de la Conception</s1><s2>Marseille</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gentet, Jean Claude" sort="Gentet, Jean Claude" uniqKey="Gentet J" first="Jean Claude" last="Gentet">Jean Claude Gentet</name><affiliation><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0399816</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0399816 INIST</idno><idno type="RBID">Pascal:08-0399816</idno><idno type="wicri:Area/PascalFrancis/Corpus">003365</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study</title><author><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="Andre">Nicolas Andre</name><affiliation><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rome, Angelique" sort="Rome, Angelique" uniqKey="Rome A" first="Angelique" last="Rome">Angelique Rome</name><affiliation><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Coze, Carole" sort="Coze, Carole" uniqKey="Coze C" first="Carole" last="Coze">Carole Coze</name><affiliation><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Padovani, Laetitia" sort="Padovani, Laetitia" uniqKey="Padovani L" first="Laetitia" last="Padovani">Laetitia Padovani</name><affiliation><inist:fA14 i1="03"><s1>Service de Radiothérapie, Hôpital de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pasquier, Eddy" sort="Pasquier, Eddy" uniqKey="Pasquier E" first="Eddy" last="Pasquier">Eddy Pasquier</name><affiliation><inist:fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Children's Cancer Institute Australia, Pharmacoproteomics Croup, Children's Hospital</s1><s2>Randwick</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Camoin, Laurence" sort="Camoin, Laurence" uniqKey="Camoin L" first="Laurence" last="Camoin">Laurence Camoin</name><affiliation><inist:fA14 i1="05"><s1>Laboratoire d'hématologie, Hôpital de la Conception</s1><s2>Marseille</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gentet, Jean Claude" sort="Gentet, Jean Claude" uniqKey="Gentet J" first="Jean Claude" last="Gentet">Jean Claude Gentet</name><affiliation><inist:fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Clinical therapeutics</title><title level="j" type="abbreviated">Clin. ther.</title><idno type="ISSN">0149-2918</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Clinical therapeutics</title><title level="j" type="abbreviated">Clin. ther.</title><idno type="ISSN">0149-2918</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Antineoplastic agent</term><term>Cancerology</term><term>Celecoxib</term><term>Child</term><term>Cyclophosphamide</term><term>Endothelial cell</term><term>Etoposide</term><term>Malignant tumor</term><term>Metronomic chemotherapy</term><term>Non steroidal antiinflammatory agent</term><term>Therapeutic protocol</term><term>Treatment resistance</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Etoposide</term><term>Cyclophosphamide</term><term>Anticancéreux</term><term>Célécoxib</term><term>Protocole thérapeutique</term><term>Enfant</term><term>Adolescent</term><term>Résistance traitement</term><term>Tumeur maligne</term><term>Cancérologie</term><term>Cellule endothéliale</term><term>Antiinflammatoire non stéroïde</term><term>Gène sis</term><term>Chimiothérapie métronomique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Metronomic chemotherapy (MC) is the administration of chemotherapy at doses below the maximal tolerated dose on a frequent schedule of administration, with no prolonged drug-free breaks. Objective: The aim of this research was to assess the effectiveness and tolerance of a metronomic etoposide/ cyclophosphamide/celecoxib regimen in children and adolescents with refractory cancer. Methods: This retrospective, single-center study evaluated the use of MC with etoposide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 1-14), cyclophosphamide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 15-28), and celecoxib 100 to 400 mg/d (days 1-28), in children with refractory, or high-risk relapsing, cancer. Adverse events were determined through laboratory analyses and investigator observations. Results: From January 2005 to December 2007, 17 children and adolescents were treated. The best responses observed were stabilizations of the disease that lasted over 20 weeks in 7 patients (41%). Most importantly, in 4 patients (24%) antalgic treatment could be transiently diminished or stopped, and in 1 patient (6%) oxygen support could be stopped for several weeks. Four grade IV platelet toxicities were noted in 3 patients; 2 grade IV anemia occurred in 2 patients (who had platelet and red blood cell transfusions before initiation of treatment); and 1 patient had grade III neutropenia. No other grade III or IV toxicities were noted. Grade II alopecia and stomatitis were observed in 1 patient and grade II vomiting was observed in 2 patients. One patient with meningeal carcinomatosis developed bilateral subdural hematoma for which the role of MC could not be ruled out. Circulating endothelial cells were elevated in 3 out of 3 patients in whom they were quantified and who were progressing while under MC. Conclusion: The MC regimen we report here was associated with disease stabilization without major toxicities. This assessment of MC in children and adolescents warrants further studies.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0149-2918</s0></fA01><fA03 i2="1"><s0>Clin. ther.</s0></fA03><fA05><s2>30</s2></fA05><fA06><s2>7</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study</s1></fA08><fA11 i1="01" i2="1"><s1>ANDRE (Nicolas)</s1></fA11><fA11 i1="02" i2="1"><s1>ROME (Angelique)</s1></fA11><fA11 i1="03" i2="1"><s1>COZE (Carole)</s1></fA11><fA11 i1="04" i2="1"><s1>PADOVANI (Laetitia)</s1></fA11><fA11 i1="05" i2="1"><s1>PASQUIER (Eddy)</s1></fA11><fA11 i1="06" i2="1"><s1>CAMOIN (Laurence)</s1></fA11><fA11 i1="07" i2="1"><s1>GENTET (Jean Claude)</s1></fA11><fA14 i1="01"><s1>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="02"><s1>INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="03"><s1>Service de Radiothérapie, Hôpital de La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="04"><s1>Children's Cancer Institute Australia, Pharmacoproteomics Croup, Children's Hospital</s1><s2>Randwick</s2><s3>AUS</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>Laboratoire d'hématologie, Hôpital de la Conception</s1><s2>Marseille</s2><s3>FRA</s3><sZ>6 aut.</sZ></fA14><fA20><s1>1336-1340</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18353</s2><s5>354000196281980150</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>12 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0399816</s0></fA47><fA60><s1>P</s1><s3>CR</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Clinical therapeutics</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Metronomic chemotherapy (MC) is the administration of chemotherapy at doses below the maximal tolerated dose on a frequent schedule of administration, with no prolonged drug-free breaks. Objective: The aim of this research was to assess the effectiveness and tolerance of a metronomic etoposide/ cyclophosphamide/celecoxib regimen in children and adolescents with refractory cancer. Methods: This retrospective, single-center study evaluated the use of MC with etoposide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 1-14), cyclophosphamide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 15-28), and celecoxib 100 to 400 mg/d (days 1-28), in children with refractory, or high-risk relapsing, cancer. Adverse events were determined through laboratory analyses and investigator observations. Results: From January 2005 to December 2007, 17 children and adolescents were treated. The best responses observed were stabilizations of the disease that lasted over 20 weeks in 7 patients (41%). Most importantly, in 4 patients (24%) antalgic treatment could be transiently diminished or stopped, and in 1 patient (6%) oxygen support could be stopped for several weeks. Four grade IV platelet toxicities were noted in 3 patients; 2 grade IV anemia occurred in 2 patients (who had platelet and red blood cell transfusions before initiation of treatment); and 1 patient had grade III neutropenia. No other grade III or IV toxicities were noted. Grade II alopecia and stomatitis were observed in 1 patient and grade II vomiting was observed in 2 patients. One patient with meningeal carcinomatosis developed bilateral subdural hematoma for which the role of MC could not be ruled out. Circulating endothelial cells were elevated in 3 out of 3 patients in whom they were quantified and who were progressing while under MC. Conclusion: The MC regimen we report here was associated with disease stabilization without major toxicities. This assessment of MC in children and adolescents warrants further studies.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Etoposide</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Etoposide</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Etopósido</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Cyclophosphamide</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Cyclophosphamide</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Ciclofosfamida</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Anticancéreux</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Antineoplastic agent</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Anticanceroso</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Célécoxib</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Celecoxib</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Celecoxib</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Protocole thérapeutique</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Therapeutic protocol</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Protocolo terapéutico</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Enfant</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Child</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Niño</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Adolescent</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Adolescent</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Adolescente</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Résistance traitement</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Treatment resistance</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Resistencia tratamiento</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cancérologie</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Cancerology</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Cancerología</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Cellule endothéliale</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Endothelial cell</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Célula endotelial</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Antiinflammatoire non stéroïde</s0><s5>23</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Non steroidal antiinflammatory agent</s0><s5>23</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Antiinflamatorio no esteroide</s0><s5>23</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Gène sis</s0><s4>INC</s4><s5>86</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Chimiothérapie métronomique</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Metronomic chemotherapy</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Human</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Antimitotique</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Antimitotic</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Antimitótico</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>DNA topoisomerase (ATP-hydrolysing)</s0><s2>FE</s2><s5>38</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>DNA topoisomerase (ATP-hydrolysing)</s0><s2>FE</s2><s5>38</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>DNA topoisomerase (ATP-hydrolysing)</s0><s2>FE</s2><s5>38</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Isomerases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Isomerases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Isomerases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0><s5>39</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Enzyme inhibitor</s0><s5>39</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Inhibidor enzima</s0><s5>39</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Dérivé de la podophyllotoxine</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Podophyllotoxin derivatives</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Podofilotoxina derivado</s0><s5>40</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Inhibiteur de la topoisomérase II</s0><s5>41</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Topoisomerase II inhibitor</s0><s5>41</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Inhibidor topoisomerase II</s0><s5>41</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Agent alkylant</s0><s5>42</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Alkylating agent</s0><s5>42</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Agente alquilante</s0><s5>42</s5></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Moutarde à l'azote</s0><s5>43</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Nitrogen mustard</s0><s5>43</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Mostaza al nitrógeno</s0><s5>43</s5></fC07><fC07 i1="12" i2="X" l="FRE"><s0>Dérivé de l'oxazaphosphinane</s0><s5>44</s5></fC07><fC07 i1="12" i2="X" l="ENG"><s0>Oxazaphosphinane derivatives</s0><s5>44</s5></fC07><fC07 i1="12" i2="X" l="SPA"><s0>Oxazafosfinano derivado</s0><s5>44</s5></fC07><fC07 i1="13" i2="X" l="FRE"><s0>Inhibiteur cyclooxygenase 2</s0><s5>45</s5></fC07><fC07 i1="13" i2="X" l="ENG"><s0>Cyclooxygenase 2 inhibitor</s0><s5>45</s5></fC07><fC07 i1="13" i2="X" l="SPA"><s0>Inhibidor cyclooxygenase 2</s0><s5>45</s5></fC07><fC07 i1="14" i2="X" l="FRE"><s0>Prostaglandin-endoperoxide synthase</s0><s2>FE</s2><s5>46</s5></fC07><fC07 i1="14" i2="X" l="ENG"><s0>Prostaglandin-endoperoxide synthase</s0><s2>FE</s2><s5>46</s5></fC07><fC07 i1="14" i2="X" l="SPA"><s0>Prostaglandin-endoperoxide synthase</s0><s2>FE</s2><s5>46</s5></fC07><fC07 i1="15" i2="X" l="FRE"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="15" i2="X" l="ENG"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="15" i2="X" l="SPA"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fN21><s1>259</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 08-0399816 INIST</NO><ET>Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study</ET><AU>ANDRE (Nicolas); ROME (Angelique); COZE (Carole); PADOVANI (Laetitia); PASQUIER (Eddy); CAMOIN (Laurence); GENTET (Jean Claude)</AU><AF>Service d'Oncologie Pédiatrique, Hôpital pour Enfants de La Timone/Marseille/France (1 aut., 2 aut., 3 aut., 7 aut.); INSERM UMR-777, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), CRO2, Université d'Aix-Marseille/Marseille/France (1 aut., 5 aut.); Service de Radiothérapie, Hôpital de La Timone/Marseille/France (4 aut.); Children's Cancer Institute Australia, Pharmacoproteomics Croup, Children's Hospital/Randwick/Australie (5 aut.); Laboratoire d'hématologie, Hôpital de la Conception/Marseille/France (6 aut.)</AF><DT>Publication en série; Correspondance, lettre; Niveau analytique</DT><SO>Clinical therapeutics; ISSN 0149-2918; Etats-Unis; Da. 2008; Vol. 30; No. 7; Pp. 1336-1340; Bibl. 12 ref.</SO><LA>Anglais</LA><EA>Background: Metronomic chemotherapy (MC) is the administration of chemotherapy at doses below the maximal tolerated dose on a frequent schedule of administration, with no prolonged drug-free breaks. Objective: The aim of this research was to assess the effectiveness and tolerance of a metronomic etoposide/ cyclophosphamide/celecoxib regimen in children and adolescents with refractory cancer. Methods: This retrospective, single-center study evaluated the use of MC with etoposide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 1-14), cyclophosphamide 25 mg/m<sup>2</sup>. d<sup>-1</sup> (days 15-28), and celecoxib 100 to 400 mg/d (days 1-28), in children with refractory, or high-risk relapsing, cancer. Adverse events were determined through laboratory analyses and investigator observations. Results: From January 2005 to December 2007, 17 children and adolescents were treated. The best responses observed were stabilizations of the disease that lasted over 20 weeks in 7 patients (41%). Most importantly, in 4 patients (24%) antalgic treatment could be transiently diminished or stopped, and in 1 patient (6%) oxygen support could be stopped for several weeks. Four grade IV platelet toxicities were noted in 3 patients; 2 grade IV anemia occurred in 2 patients (who had platelet and red blood cell transfusions before initiation of treatment); and 1 patient had grade III neutropenia. No other grade III or IV toxicities were noted. Grade II alopecia and stomatitis were observed in 1 patient and grade II vomiting was observed in 2 patients. One patient with meningeal carcinomatosis developed bilateral subdural hematoma for which the role of MC could not be ruled out. Circulating endothelial cells were elevated in 3 out of 3 patients in whom they were quantified and who were progressing while under MC. Conclusion: The MC regimen we report here was associated with disease stabilization without major toxicities. This assessment of MC in children and adolescents warrants further studies.</EA><CC>002B02</CC><FD>Etoposide; Cyclophosphamide; Anticancéreux; Célécoxib; Protocole thérapeutique; Enfant; Adolescent; Résistance traitement; Tumeur maligne; Cancérologie; Cellule endothéliale; Antiinflammatoire non stéroïde; Gène sis; Chimiothérapie métronomique</FD><FG>Homme; Cancer; Antimitotique; DNA topoisomerase (ATP-hydrolysing); Isomerases; Enzyme; Inhibiteur enzyme; Dérivé de la podophyllotoxine; Inhibiteur de la topoisomérase II; Agent alkylant; Moutarde à l'azote; Dérivé de l'oxazaphosphinane; Inhibiteur cyclooxygenase 2; Prostaglandin-endoperoxide synthase; Oxidoreductases</FG><ED>Etoposide; Cyclophosphamide; Antineoplastic agent; Celecoxib; Therapeutic protocol; Child; Adolescent; Treatment resistance; Malignant tumor; Cancerology; Endothelial cell; Non steroidal antiinflammatory agent; Metronomic chemotherapy</ED><EG>Human; Cancer; Antimitotic; DNA topoisomerase (ATP-hydrolysing); Isomerases; Enzyme; Enzyme inhibitor; Podophyllotoxin derivatives; Topoisomerase II inhibitor; Alkylating agent; Nitrogen mustard; Oxazaphosphinane derivatives; Cyclooxygenase 2 inhibitor; Prostaglandin-endoperoxide synthase; Oxidoreductases</EG><SD>Etopósido; Ciclofosfamida; Anticanceroso; Celecoxib; Protocolo terapéutico; Niño; Adolescente; Resistencia tratamiento; Tumor maligno; Cancerología; Célula endotelial; Antiinflamatorio no esteroide</SD><LO>INIST-18353.354000196281980150</LO><ID>08-0399816</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003365 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003365 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:08-0399816
|texte= Metronomic Etoposide/Cyclophosphamide/Celecoxib Regimen Given to Children and Adolescents with Refractory Cancer : A Preliminary Monocentric Study
}}
| This area was generated with Dilib version V0.6.33. |  |